Under the contract, Evotec is expected to use its fragment-based drug discovery platform, EVOlution to the programme, which will used to investigate protein-protein interactions on targets selected by Shionogi.
Evotec claims that its EVOlution drug discovery platform combines biochemical and biophysical techniques including nuclear magnetic resonance (NMR), surface plasmon resonance (SPR) and X-ray crystallography.
Evotec COO Mario Polywka said that their proprietary fragment-based drug discovery platform has shown that it adds significant value to the partner’s programmes and they look forward to supporting Shionogi in finding novel treatments for inflammation and infectious diseases.